CY1122416T1 - Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης - Google Patents

Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης

Info

Publication number
CY1122416T1
CY1122416T1 CY20191101278T CY191101278T CY1122416T1 CY 1122416 T1 CY1122416 T1 CY 1122416T1 CY 20191101278 T CY20191101278 T CY 20191101278T CY 191101278 T CY191101278 T CY 191101278T CY 1122416 T1 CY1122416 T1 CY 1122416T1
Authority
CY
Cyprus
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
CY20191101278T
Other languages
English (en)
Inventor
Michael Gruss
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1122416T1 publication Critical patent/CY1122416T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Η εφεύρεση αφορά κρυσταλλικές τροποποιήσεις (1R,2Ρ)-3-(3-Διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινόλης, φαρμακευτικές συνθέσεις οι οποίες περιέχουν αυτές τις τροποποιήσεις, καθώς επίσης τη χρήση αυτών.
CY20191101278T 2007-12-07 2019-12-04 Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης CY1122416T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023728 2007-12-07
PCT/EP2008/010330 WO2009071310A1 (de) 2007-12-07 2008-12-05 Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EP08857298.7A EP2240431B1 (de) 2007-12-07 2008-12-05 Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Publications (1)

Publication Number Publication Date
CY1122416T1 true CY1122416T1 (el) 2021-01-27

Family

ID=39272207

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100414T CY1118976T1 (el) 2007-12-07 2017-04-07 Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
CY20191101278T CY1122416T1 (el) 2007-12-07 2019-12-04 Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100414T CY1118976T1 (el) 2007-12-07 2017-04-07 Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης

Country Status (14)

Country Link
US (1) US8134032B2 (el)
EP (2) EP2240431B1 (el)
CN (3) CN101939287B (el)
CY (2) CY1118976T1 (el)
DK (2) DK2240431T3 (el)
ES (2) ES2623413T3 (el)
HR (2) HRP20170481T1 (el)
HU (2) HUE047275T2 (el)
IL (2) IL206197A (el)
LT (1) LT2240431T (el)
PL (2) PL2240431T3 (el)
PT (2) PT3173400T (el)
SI (2) SI3173400T1 (el)
WO (1) WO2009071310A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2014023652A1 (en) * 2012-08-06 2014-02-13 Ratiopharm Gmbh Pharmaceutical formulation comprising tapentadol and cyclodextrin
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
ES2937740T3 (es) 2016-04-19 2023-03-30 Ratiopharm Gmbh Fosfato de tapentadol cristalino

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1027666C (zh) * 1993-02-20 1995-02-15 袁晓辉 高分子聚合物正温度系数热敏电阻材料
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10326097A1 (de) * 2003-06-06 2005-01-05 Grünenthal GmbH Verfahren zur Herstellung von Dimethyl-(3-aryl-butyl)-aminverbindungen
ES2291780T3 (es) * 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
DE102005034974A1 (de) * 2005-07-22 2007-04-19 Grünenthal GmbH Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination

Also Published As

Publication number Publication date
EP2240431B1 (de) 2017-01-25
EP3173400B1 (de) 2019-11-06
EP2240431A1 (de) 2010-10-20
IL237478A0 (en) 2015-04-30
DK2240431T3 (en) 2017-04-10
SI2240431T1 (sl) 2017-05-31
HRP20170481T1 (hr) 2017-05-19
HUE047275T2 (hu) 2020-04-28
SI3173400T1 (sl) 2020-01-31
CN104447360A (zh) 2015-03-25
ES2623413T3 (es) 2017-07-11
LT2240431T (lt) 2017-04-10
WO2009071310A1 (de) 2009-06-11
CN104447361B (zh) 2017-04-12
IL206197A (en) 2015-03-31
ES2764451T3 (es) 2020-06-03
PT2240431T (pt) 2017-05-03
DK3173400T3 (da) 2019-11-25
HUE031126T2 (en) 2017-07-28
EP3173400A1 (de) 2017-05-31
HRP20200067T1 (hr) 2020-04-03
PL3173400T3 (pl) 2020-05-18
CY1118976T1 (el) 2018-01-10
IL206197A0 (en) 2010-12-30
CN104447361A (zh) 2015-03-25
CN101939287A (zh) 2011-01-05
CN101939287B (zh) 2014-10-22
PL2240431T3 (pl) 2017-07-31
US20090149534A1 (en) 2009-06-11
US8134032B2 (en) 2012-03-13
CN104447360B (zh) 2017-04-12
PT3173400T (pt) 2019-12-13

Similar Documents

Publication Publication Date Title
CY1122416T1 (el) Φαρμακα τα οποια περιεχουν κρυσταλλικες τροποποιησεις (1r,2r)-3-(3-δimeθyλamino-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1124873T1 (el) Διεργασια για την παρασκευη (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
CY1106929T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
EA201170772A1 (ru) Органические соединения
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CY1115455T1 (el) Χρησιμοποιηση ενωσεων 1-φαινυλο-3-διμεθυλαμινο-προπανιου για τη θεραπεια του πονου νευροπαθειας
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
ATE528989T1 (de) Kristalline feste rasagilin-base
EA200870599A1 (ru) Стабильные препараты лаквинимода
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
BRPI0908637B8 (pt) composto e composição farmacêutica do mesmo
UY31524A1 (es) Nuevos compuestos 010
MX2009011165A (es) Formulaciones farmaceuticas que contienen derivados del acido lipoico.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
SE0401762D0 (sv) Novel compounds
EA200801414A1 (ru) Кальцилитические соединения
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas